Lockheed Martin is in a recovery phase within a broader range-bound structure, with the current price of $505.41 sitting just 9.9% above its 52-week low of $437.25 and 27.0% below its 52-week high of $692.00 — placing it at roughly 26.7% of its 52-week range. The 1-year price change of +1.21% masks significant intra-year volatility, including a max drawdown of -27.35%, indicating the stock has round-tripped a substantial decline and is now attempting to rebuild momentum from a deeply discounted base. This positioning near the lower quartile of the annual range suggests the stock is neither overextended nor in free-fall, but rather in a consolidation zone where value-oriented buyers have begun to accumulate. Recent momentum is decidedly negative and diverging sharply from the longer-term trend: the 1-month change of -4.92% and 3-month change of -7.42% contrast with the positive 1-year return, signaling a loss of near-term conviction even as the annual trend remains marginally positive. The 6-month change of -18.85% reveals the severity of the mid-year selloff, and relative strength versus SPY is negative across every measured window — -5.51% over 1 month, -10.76% over 3 months, and a striking -36.20% over 6 months — confirming that capital has rotated decisively away from LMT and into broader market beta. The divergence between the flat 1-year return and the sharply negative 1-month and 3-month readings suggests the stock is in a corrective pullback within a longer-term recovery, and the absence of a meaningful bounce despite the July earnings beat implies the market is demanding either stronger forward guidance or a more attractive entry valuation. Key technical levels are well-defined: the 52-week low at $437.25 represents the critical support zone, and a breakdown below that level would signal a deeper bearish repricing potentially toward the $400 psychological area, while the 52-week high at $692.00 stands as the primary resistance ceiling. A breakout above $692 would require a fundamental catalyst — likely a major contract award or a significant upward revision to defense budget expectations — and would confirm a new uptrend. The beta of 0.104 is extraordinarily low, indicating the stock has historically exhibited almost no correlation to broad market moves, which makes it an effective portfolio diversifier but also means it will not benefit from general market rallies; for position sizing, this low beta suggests the stock's risk is almost entirely idiosyncratic (program-specific, budget-cycle, and geopolitical), not systematic.

Lockheed Martin's revenue trajectory is reaccelerating meaningfully, with Q2 2026 revenue of $20.06 billion representing 10.51% year-over-year growth — a sharp acceleration from the prior-year Q2 figure of $18.16 billion. The sequential trend is equally constructive: Q1 2026 revenue of $18.02 billion grew to $20.06 billion in Q2, and the Q4 2025 print of $20.33 billion confirms the company is operating at a consistently higher revenue base than the $17-18 billion quarterly levels seen throughout much of 2024 and early 2025. Segment data shows Aeronautics as the dominant contributor at $8.11 billion, followed by Rotary and Mission Systems at $4.35 billion, Missiles and Fire Control at $4.10 billion, and Space at $3.50 billion — a diversified mix that reduces single-program concentration risk even as the F-35 remains the anchor. The 3.2x book-to-bill ratio cited in recent coverage implies that revenue growth should persist well into 2027 and beyond, as the backlog converts to recognized revenue. Profitability has inflected dramatically: Q2 2026 net income of $1.836 billion on $20.06 billion in revenue yields a 9.15% net margin, a massive improvement from the $342 million (1.88% net margin) reported in Q2 2025, which was depressed by a $1.6 billion classified program charge. Gross margin of 12.19% in Q2 2026 is consistent with the 11.5-12.4% range seen across recent quarters, reflecting the cost-plus and fixed-price mix typical of defense prime contracting, where gross margins are structurally lower than commercial aerospace but operating leverage is driven by volume and program mix. The operating margin of 12.36% and EBITDA of $2.479 billion (12.36% EBITDA margin) confirm that the earnings recovery is broad-based, and the trailing net margin of 6.68% understates current run-rate profitability given the one-time charges in prior periods. Balance sheet health presents a mixed picture: the debt-to-equity ratio of 3.23x is elevated and reflects the company's capital-return-heavy strategy (dividends paid of $796 million and debt repayment of $168 million in Q2 alone), but the current ratio of 1.09x and interest coverage of 9.3x indicate adequate near-term liquidity and debt service capacity. Free cash flow on a trailing-twelve-month basis stands at $8.729 billion, and Q2 2026 free cash flow of $2.917 billion on operating cash flow of $3.235 billion demonstrates strong cash generation, though the Q1 2026 free cash flow was negative at -$291 million due to working capital swings (inventory build of $727 million and receivables increase of $1.579 billion). The ROE of 74.65% is exceptionally high but is inflated by the leveraged capital structure (equity multiplier of 7.12x), so it should be interpreted alongside the debt-to-equity ratio rather than in isolation; the more conservative ROA of 8.64% provides a cleaner view of asset-level profitability.